For years, we were told it was a period problem.
The acne. The weight that wouldn't move. The hair in places we were taught to be ashamed of. The cycles that arrived late, or early, or not at all. We were shamed for it, laughed at for it, and sent home with the same advice every time: lose weight, get married, have a baby, you'll be fine.
"Aap married hain?" The question opens many appointments. As if a hormonal disorder only deserves treatment once a husband is involved. As if our bodies are filing cabinets for future pregnancies and nothing else. Say no, and the conversation often ends before it begins, because what is there to fix in a woman who isn't trying to make someone else?
On May 12, a paper in The Lancet announced that polycystic ovary syndrome, the condition one in eight women live with, will no longer be called polycystic ovary syndrome. Its new name is polyendocrine metabolic ovarian syndrome, or PMOS. The change was led by Helena Teede, an endocrinologist at Monash University in Australia, and built on 14 years of work involving dozens of professional societies and more than 20,000 patients, doctors, and researchers across six continents.
The term "polycystic" implied cysts on the ovaries. But the structures seen on ultrasounds are not ovarian cysts in the conventional medical sense; they are immature follicles. Researchers involved in the renaming effort argued that the old terminology misrepresented the condition and narrowed public understanding of it. Under evolving diagnostic guidelines, many women may no longer need ovarian ultrasounds for diagnosis if irregular cycles and excess androgen levels are already present.
What the old name buried was the rest of the condition. PCOS is not, and never was, a disease of the ovaries with some side effects. It is an endocrine and metabolic disorder that involves the ovaries. Insulin resistance affects roughly 85% of women with the condition. The risks of type 2 diabetes, cardiovascular disease, stroke, depression, and anxiety are all elevated. Up to 70% of women with the condition are still estimated to be undiagnosed.
If the old name harmed women globally, it harmed South Asian women specifically. Studies have found polycystic ovarian morphology in roughly 52% of women of South Asian origin, more than twice the rate reported in Caucasian populations. Pakistani studies, depending on hospital and diagnostic criteria, report prevalence anywhere from 18% to over 50% among reproductive-age women.
South Asian women also tend to develop the condition earlier, present with more severe metabolic symptoms, and carry a higher baseline risk of insulin resistance and type 2 diabetes.
A 2024 systematic analysis of the Global Burden of Disease found PCOS prevalence rising steadily across South Asia, with India carrying the highest burden in the region.
But a name change in The Lancet does not automatically arrive in Lahore, Karachi, or Quetta. PMOS is expected to be formally integrated into international guidelines by 2028.
In Pakistan, many women with the condition are not diagnosed by endocrinologists because there are relatively few specialists to go around.
Much of the work falls to gynecologists, general practitioners, and increasingly to social-media wellness influencers promoting spearmint tea, inositol supplements, and hormonal "healing" plans online.
The women walking into a gynecologist's office next month will not necessarily be greeted with a different question. It may still be "aap married hain?" The chart may eventually say PMOS instead of PCOS, once forms are reprinted, textbooks are updated, and the next cohort of medical students learns the new acronym.
The condition behind both names will remain the same one many women have been told, for years, was either nothing or their own fault.
The rename matters. Words in medicine shape which doctors get consulted, which research gets funded, and which symptoms get taken seriously.
But some clinicians have also cautioned that changing terminology alone will not fix gaps in diagnosis, access, or care. After 14 years of advocacy and global consensus, though, the disease has finally been called something closer to what it is.